Where 25-Hydroxyvitamin D is reported
| Condition | Direction | Compared against | Associated symptoms | Source |
|---|---|---|---|---|
| Asthma | ↕ inconsistent | obese asthmatic children with sufficient vitamin D | lower Forced Expiratory Volume in the first second, lower Functional Residual Capacity, lower Total Lung Capacity | Lautenbacher et al. 2016 |
| Low Back Pain | ↓ reduced | matched healthy controls | chronic low back pain | Lotfi et al. 2007 |
| Major Depressive Disorder | ↓ reduced | healthy controls | major depressive disorder | He et al. 2020 |
| Migraine | ↓ reduced | healthy controls | — | Liampas et al. 2020 |
| Multiple Sclerosis | ↓ reduced | healthy controls | — | Clarke et al. 2020 |
Frequently asked questions
In which conditions is 25-Hydroxyvitamin D altered?
In the OSMF atlas 25-Hydroxyvitamin D is reported in Asthma, Low Back Pain, Major Depressive Disorder, Migraine, Multiple Sclerosis. It is reduced in 4, mixed in 1 across 5 entries.
Does 25-Hydroxyvitamin D point to one specific diagnosis?
No. Because 25-Hydroxyvitamin D changes in several conditions (Asthma, Low Back Pain, Major Depressive Disorder, Migraine, Multiple Sclerosis), an abnormal result cannot identify which condition, if any, is present. It must be interpreted with symptoms, history and other tests.
Is there a standard clinical test for 25-Hydroxyvitamin D?
The atlas entries for 25-Hydroxyvitamin D do not carry a LOINC code, which usually means the marker was measured with research assays or study-specific methods rather than a routine clinical panel.
Is one abnormal 25-Hydroxyvitamin D result diagnostic?
No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.
Cite this page
Subscribe on Substack
Last reviewed: 2026-10-08 · Browse: Biomarker Index · All marker pages · Biomarker Atlas
Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.